NVCR — NovoCure Ltd
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1645113 ·
Jersey
Last close
$11.14
Market Cap
$1.30B
52W High
$21.45
52W Low
$9.82
ADV30
1,884,938
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 193,399,000 | 148,870,000 | -6,171,000 | -10,435,000 | 828,708,000 | 96,734,000 | 478,095,000 |
| Jun 2026 | 183,584,000 | 142,478,000 | -10,562,000 | -15,658,000 | 795,191,000 | 93,701,000 | 457,099,000 |
| Mar 2026 | 174,055,000 | 135,126,000 | -67,420,000 | -71,138,000 | 787,926,000 | 87,527,000 | 457,209,000 |
| Dec 2025 | 174,350,000 | 132,193,000 | -40,393,000 | -24,499,000 | 804,326,000 | 93,548,000 | 463,860,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,815,000
Investing CF
$409,131,000
Financing CF
$-454,595,000
CapEx
$-22,619,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.30
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,377,153,000
Inventory
$42,224,000
Receivables
$145,821,000
ST Investments
$346,858,000
EBIT TTM
$-119,809,000
Pretax Income TTM
$-152,686,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$725,388,032
EBITDA
$-105,790,000
Free Cash Flow
$-89,941,376
Enterprise Value
$1,305,519,872
Total Cash
$463,479,008
Total Debt
$231,554,000
Shares Out
116,915,959
Trailing EPS
$-1.06
Book Value
$3.00
ROE
-35.2%
ROA
-6.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 655,353,000 | -153,800,000 | -136,227,000 | 804,326,000 | 463,860,000 | 340,466,000 | -49,031,000 |
| Dec 2024 | 605,220,000 | -170,496,000 | -168,627,000 | 1,240,784,000 | 880,605,000 | 360,179,000 | -26,369,000 |
| Dec 2023 | 509,338,000 | -232,870,000 | -207,043,000 | 1,146,129,000 | 783,633,000 | 362,496,000 | -73,336,000 |
| Dec 2022 | 537,840,000 | -89,523,000 | -92,534,000 | 1,191,648,000 | 750,478,000 | 441,170,000 | 30,788,000 |
TTM Snapshot
Revenues TTM
$699,193,000
NetIncome TTM
$-148,565,000
OpCashFlow TTM
—
Assets (Latest)
$795,191,000
Forward EPS
$-0.78
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $16.00 · spot: $10.73 · call volume: 53 · put volume: 48
Expected Move to 2027-01-15:
±$15.75
(146.78%) —
implied range
$-5.02 –
$26.48
· ATM straddle on $11.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRCT | PROCEPT BioRobotics Corp | $1.37B | $23.78 | — |
| CDRE | Cadre Holdings, Inc. | $1.39B | $32.41 | — |
| BFLY | Butterfly Network, Inc. | $1.41B | $5.75 | — |
| TNDM | TANDEM DIABETES CARE INC | $1.19B | $17.06 | — |
| CNMD | CONMED Corp | $1.44B | $48.39 | — |
News headlines (Yahoo Finance, 1h cache)
JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic Cancer
2026-11-13 16:30 · Yahoo
NovoCure (NVCR) Stock May Trade At A Discount Despite FDA Setback
2026-11-12 23:26 · Yahoo
FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.
2026-11-10 19:10 · Yahoo
Novocure denied FDA approval for metastatic cancer treatment
2026-11-09 16:40 · Yahoo
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer
2026-11-09 12:00 · Yahoo
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
2026-11-02 13:15 · Yahoo
NovoCure: 3 Key Takeaways for Long-Term Investors
2026-11-02 02:43 · Yahoo
NovoCure (NVCR) Q3 Results Spark Margin Turn Debate
2026-10-31 08:12 · Yahoo
NovoCure Q3 Earnings Call Highlights
2026-10-29 20:14 · Yahoo
NovoCure (NVCR) Q3 2026 Earnings Call Transcript
2026-10-29 18:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.